AbbVie company profile
Company profile
AbbVie has 57,000 employees and is headquartered in North Chicago, United States.
The United States accounts for 76.2% of the sales of AbbVie Inc., while other countries contribute 9.4%, and Germany, Japan, Canada, China, France and the United Kingdom each represent between 1.0% and 2.8%. The company researches, develops, manufactures and sells medicines and therapies worldwide. Its main products include Skyrizi and Rinvoq for autoimmune and inflammatory diseases, Imbruvica, Venclexta and Epkinly for blood cancers, Vraylar for psychiatric disorders, Ubrelvy and Qulipta for migraine, Mavyret for hepatitis C, and Creon, a pancreatic enzyme therapy. It also sells aesthetic brands such as Botox Cosmetic and Juvederm, along with eye care products including Ozurdex.
In the fiscal year ended December 2025, AbbVie reported revenue of $61.2 billion, up 8.6% from the previous year, and net income of $4.2 billion. The company employs 57,000 people and is headquartered in North Chicago, Illinois. It was incorporated in 2012.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Headquarters
- 1 North Waukegan Road, 60064-6400, North Chicago
- Employees
- 57,000
- Chief executive
- Robert Michael
- Founded
- 2012
- Fiscal year
- January - December
- Listing
- ABBV · NYSE
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US00287Y1091
- Website
- abbvie.com
AbbVie and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| AbbVieABBV | United States | $517.59B | 57,000 | 36.6% | 50.4 |
| Johnson & JohnsonJNJ | United States | $680.19B | 138,200 | 26.6% | 42.9 |
| Merck & Co.MRK | United States | $356.13B | 73,000 | 35.2% | 144.5 |
| AmgenAMGN | United States | $250.07B | 31,500 | 34.1% | 26.8 |
| Gilead SciencesGILD | United States | $211.18B | 17,000 | 38.2% | — |
| Eli LillyLLY | United States | $1.28T | 50,000 | 51.3% | 46.5 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
